Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

BACKGROUND: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Public Health
Auteurs principaux: Sodré, Sávio Lima, Barbosa, Italo Antunes França, Pacheco, Israel Emiliano, Ferreira, Felipe de Queiroz Tavares, David, Milton Agrizzi, Nascimento, Mauricio Abujamra, Arieta, Carlos Eduardo Leite, Vasconcellos, Jose Paulo Cabral de
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6740002/
https://ncbi.nlm.nih.gov/pubmed/31510981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12889-019-7562-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires